Analytical Data
-
基因名
MN1
- Application
-
别名
AA003644; AA009236; dJ353E16.2; Meningioma (disrupted in balanced translocation) 1; Meningioma (translocation balanced); Meningioma 1 ; meningioma chromosome region 1; MGCR; MGCR1; MGCR1-PEN; MN1; MN1_HUMAN; Probable tumor suppressor protein MN1; RGD1565571
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q10571
-
表达区间
1-293 aa
-
氨基酸序列
MRELLELSCCHSCPFSSTAAAKCFAGLLNKHPAGQQLDEFLQLAVDKVEAGLGSGPCRSQAFTLLLWVTKALVLRYHPLSSCLTARLMGLLSDPELGPAAADGFSLLMSDCTDVLTRAGHAEVRIMFRQRFFTDNVPALVQGFHAAPPDVKPNYLKGLSHVLNRLPKPVLLPELPTLLSLLLEALSCPDCVVQLSTLSCLQPLLLEAPQVMSLHVDTLVTKFLNLSSSPSMAVRIAALQCMHALTRLPTPVLLPYKPQVIRALAKSLDDKKRLVRKEAVSARGEWFLLGSPGS
-
分子量
57.97 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The MN1 recombinant protein has emerged as a subject of interest due to its pivotal role in hematopoiesis and leukaemogenesis. MN1 gene, located on chromosome 22, is known to be involved in processes critical for blood cell development and differentiation, making it an important focus in understanding various blood disorders, particularly acute myeloid leukaemia (AML). Research has indicated that the overexpression of MN1 can contribute to the transformation of hematopoietic progenitor cells, leading to malignant states. This association highlights the significance of MN1 in oncogenic signaling pathways. Consequently, scientists have been investigating MN1 as a potential therapeutic target, aiming to develop targeted treatments for leukaemia that could minimize survival-related pathways activated by MN1. Additionally, synthetic biology techniques to produce MN1 recombinant proteins have enabled detailed functional analyses, contributing to insights into its biochemical properties, interactions, and the molecular mechanisms underlying its role in disease. Understanding the expression patterns and regulatory mechanisms of MN1 not only aids in identifying biomarkers for disease prognosis but also opens avenues for innovative therapeutic strategies in the management of hematological malignancies.
